287 related articles for article (PubMed ID: 12460229)
1. Bisphosphonate therapy in multiple myeloma: past, present, future.
Jantunen E
Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate therapy in multiple myeloma.
Laakso M; Jantunen E
Acta Oncol; 1996; 35 Suppl 5():55-6. PubMed ID: 9142966
[TBL] [Abstract][Full Text] [Related]
4. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in multiple myeloma.
Berenson JR
Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
[TBL] [Abstract][Full Text] [Related]
7. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
Morgan GJ; Child JA; Gregory WM; Szubert AJ; Cocks K; Bell SE; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Wu P; Davies FE;
Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate therapy in the oncology setting.
Lipton A
Expert Opin Emerg Drugs; 2003 Nov; 8(2):469-88. PubMed ID: 14662000
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in multiple myeloma.
Kanis JA; McCloskey EV
Cancer; 2000 Jun; 88(12 Suppl):3022-32. PubMed ID: 10898347
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
11. Use of clodronate in multiple myeloma.
Jantunen E; Lahtinen R; Laakso M
Leuk Lymphoma; 1995 Oct; 19(3-4):207-11. PubMed ID: 8535211
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
Cafro AM; Barbarano L; Nosari AM; D'Avanzo G; Nichelatti M; Bibas M; Gaglioti D; Taroni A; Riva F; Morra E; Andriani A
Clin Lymphoma Myeloma; 2008 Apr; 8(2):111-6. PubMed ID: 18501105
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Palmieri C; Fullarton JR; Brown J
Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
[TBL] [Abstract][Full Text] [Related]
14. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
17. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
18. [Bisphosphonates and bone metastases].
Lortholary A; Jadaud E; Berthaud P
Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.
Merlini G; Parrinello GA; Piccinini L; Crema F; Fiorentini ML; Riccardi A; Pavesi F; Novazzi F; Silingardi V; Ascari E
Hematol Oncol; 1990; 8(1):23-30. PubMed ID: 2137106
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
